TriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (NASDAQ:TCGX) ("TCGX"), a publicly listed special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") to the U.S. Securities and Exchange Commission ("SEC").

The submission of the Registration Statement marks an important milestone toward the completion of the previously announced proposed business combination between TriGemX Bio and TCGX that would result in TriGemX Bio becoming a publicly traded company listed on Nasdaq under the ticker symbol "TGEM".

The closing of the business combination is expected to occur in the first quarter of 2027 and is subject to the receipt of the requisite approval of TCGX’s shareholders, the Registration Statement being declared effective by the SEC, approval by Nasdaq to list the securities of the combined company, and other customary closing conditions.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.